The bioavailability of oral fludarabine phosphate is unaffected by food

Hematology Journal

Volumn 2, Issue 5, 2001, Pages 316-321

  Oscier, D ^a   Orchard, J A ^a   Culligan, D ^a   Cunningham, D ^a   Johnson, S ^a   Parker, A ^a   Klein, M ^a   Gieschen, H ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

Fludarabine phosphate; Food effect; Oral formulation; Pharmacokinetics

Indexed keywords

FLUDARABINE PHOSPHATE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GRADING; CANCER PATIENT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; FEEDING; FEMALE; FEVER; FOOD; HUMAN; INFECTION; MALE; MEDICAL ASSESSMENT; NAUSEA; NONHODGKIN LYMPHOMA; PAIN; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STOMACH; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIDARABINE PHOSPHATE;

EID: 0034780618     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200113     Document Type: Article

References (21)

1. Treatment of B-cell chronic lymphocytic leukaemia: Current status and future perspectives
2. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment
3. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: Five-year follow-up report
4. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent
5. Clinical experience with fludarabine in hemato-oncology
6. Fludarabine in untreated and previously treated B-CLL patients: A report on efficacy and toxicity
7. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: The Spanish Group experience
8. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative group on CLL
9. International randomized trials of chemotherapy for CLL
10. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: Results of an Eastern Cooperative Oncology Group study
11. Chronic lymphocytic leukemia
12. Activity of fludarabine in refractory chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. The Jerusalem experience
13. Fludarabine: A phase II trial in patients with previously treated low-grade lymphoma
14. First line fludarabine treatment of symptomatic chronic lymphoproliferative diseases: Clinical results and molecular analysis of minimal residual disease
15. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia
16. 2-F-ara-A pharmacokinetics including systemic availability during treatment with fludarabine phosphate given either perorally as an immediate release tablet formulation, or intravenously as a solution
17. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies
18. Plasma and cellular bioavailability of oral fludarabine
19. A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids
20. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: A phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group
21. Treatment of alkylator resistant chronic lymphocytic leukemia with oral fludarabine phosphate